Cross-Sector entity
regulation is the sole category represented across all 1 tracked stories. Africa Centres for Disease Control and Prevention is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each.
1 verified story tracked
Last mentioned: Jul 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Africa Centres for Disease Control and Prevention is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Coalition for Epidemic Preparedness Innovations appears in 1 tracked Cross-Sector story from July 20, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Coalition for Epidemic Preparedness Innovations. Shared-story counts are live from our verified record — not editorial picks.
First-in-Human Trial Begins
A Phase 1 clinical trial of the ChAdOx1-biEBOV vaccine, enrolling 50 healthy adults, commences with 4,000 doses supplied by the Serum Institute of India.
WHO Declares Public Health Emergency
The World Health Organization declares the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), accelerating vaccine development and funding.
A phase 1 trial of an adenovirus-vectored vaccine for the Bundibugyo Ebola strain is underway, enrolling 50 adults. With 620,000 doses pre-manufactured, the trial highlights rapid pandemic response but underscores immediate public health challenges as the outbreak’s death toll exceeds 700.
Source: deccanchronicle.com · seattletimes.com
